Extrapolation of in vitro antimutagenicity to the in vivo situation: the case for anthraflavic acid.
Ioannides
C
C
Division of Toxicology, School of Biological Sciences, University of Surrey, Guildford, United Kingdom.
Ayrton
A D
AD
Lewis
D F
DF
Walker
R
R
D000818:Animals; D000880:Anthraquinones / Q000494:pharmacology*; D016588:Anticarcinogenic Agents / Q000494:pharmacology; D016587:Antimutagenic Agents / Q000494:pharmacology*; D001140:Aroclors / Q000494:pharmacology; D001711:Biotransformation; D002273:Carcinogens / Q000633:toxicity*; D020111:Chlorodiphenyl (54% Chlorine); D008862:Microsomes, Liver / Q000187:drug effects / Q000378:metabolism; D006899:Mixed Function Oxygenases / Q000378:metabolism*; D009152:Mutagenicity Tests / Q000379:methods; D011804:Quinolines / Q000633:toxicity*; D051381:Rats; D012486:Salmonella typhimurium / Q000187:drug effects
D000880:Anthraquinones; D016588:Anticarcinogenic Agents; D016587:Antimutagenic Agents; D001140:Aroclors; D002273:Carcinogens; D011804:Quinolines; D020111:Chlorodiphenyl (54% Chlorine); C029216:2-amino-3-methylimidazo(4,5-f)quinoline; D006899:Mixed Function Oxygenases; C034889:2,6-dihydroxyanthraquinone